Morphic's $80M round paves way for integrin clinical studies

Morphic Therapeutic (Waltham, Mass.) raised $80 million on Sept. 25 in a series B round led by existing investor Omega Funds and new investor Novo Holdings A/S (Hellerup, Denmark). New investors Invus and EcoR1 Capital, and existing investors SR One, Pfizer Ventures, AbbVie Ventures, Polaris Partners, computational chemistry company Schrödinger Inc. (New York, N.Y.), ShangPharma Innovation Inc. (South San Francisco, Calif.) and co-founder Timothy Springer also participated.

Morphic is developing oral small molecule integrin inhibitors by combining an understanding of the structural biology of integrins with computational chemistry (see "Integrins Go Oral")...